ReviewSeminars in nuclear medicine2018
Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging.
Review in Seminars in nuclear medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cerenkov luminescence microscopy: A novel approach for high-resolution radiotracer imaging.iScience · 2025Article
- Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- ROS-activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm.Advanced therapeutics · 2024Article
- Luminescence Probes in Bio-Applications: From Principle to Practice.Biosensors · 2024Review
- Investigation of Photodynamic Therapy Promoted by Cherenkov Light Activated Photosensitizers-New Aspects and Revelations.Pharmaceutics · 2024Article
- Detection of Shortwave-Infrared Cerenkov Luminescence from Medical Isotopes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Psoralen as a Photosensitizers for Photodynamic Therapy by Means of In Vitro Cherenkov Light.International journal of molecular sciences · 2022Article
- Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.Nature biomedical engineering · 2022Observational
- In situ lymphoma imaging in a spontaneous mouse model using the Cerenkov Luminescence of F-18 and Ga-67 isotopes.Scientific reports · 2021Article
- Intraperitoneal Glucose Transport to Micrometastasis: A Multimodal In Vivo Imaging Investigation in a Mouse Lymphoma Model.International journal of molecular sciences · 2021Article
- Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers.Molecular pharmaceutics · 2021Article
- A review of recent and emerging approaches for the clinical application of Cerenkov luminescence imaging.Frontiers in physics · 2021Article
- Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.Molecules (Basel, Switzerland) · 2020Article
- Theoretical and experimental characterization of emission and transmission spectra of Cerenkov radiation generated by 177Lu in tissue.Journal of biomedical optics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cerenkov luminescence (CL) is blue glow light produced by charged subatomic particles travelling faster than the phase velocity of light in a dielectric medium such as water or tissue. CL was first discovered in 1934, but for biomedical research it was recognized only in 2009 after advances in optical camera sensors brought the required high sensitivity. Recently, applications of CL from clinical radionuclides have been rapidly expanding to include not only preclinical and clinical biomedical imaging but also an approach to therapy. Cerenkov Luminescence Imaging (CLI) utilizes CL generated from clinically relevant radionuclides alongside optical imaging instrumentation. CLI is advantageous over traditional nuclear imaging methods in terms of infrastructure cost, resolution, and imaging time. Furthermore, CLI is a truly multimodal imaging method where the same agent can be detected by two independent modalities, with optical (CL) imaging and with positron emission tomography (PET) imaging. CL has been combined with small molecules, biomolecules and nanoparticles to improve diagnosis and therapy in cancer research. Here, we cover the fundamental breakthroughs and recent advances in reagents and instrumentation methods for CLI as well as therapeutic application of CL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.